Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia - PubMed (original) (raw)
. 2006 Oct 1;24(28):4634-41.
doi: 10.1200/JCO.2006.06.9492.
Thomas E Witzig, Stephanie R Fink, Robert B Jenkins, Sarah F Paternoster, Stephanie A Smoley, Kimberly J Stockero, Danielle M Nast, Heather C Flynn, Renee C Tschumper, Susan Geyer, Clive S Zent, Tim G Call, Diane F Jelinek, Neil E Kay, Gordon W Dewald
Affiliations
- PMID: 17008705
- DOI: 10.1200/JCO.2006.06.9492
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
Tait D Shanafelt et al. J Clin Oncol. 2006.
Abstract
Purpose: Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) can identify patients with chronic lymphocytic leukemia (CLL) who will experience a more aggressive disease course. Other studies suggest that patients may acquire chromosome abnormalities during the course of their disease. There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH.
Patients and methods: Between 1994 and 2002, we enrolled 159 patients with previously untreated CLL (83% Rai stage 0/I) on a prospective trial evaluating clonal evolution by FISH. Patients provided baseline and follow-up specimens for FISH testing during 2 to 12 years.
Results: Chromosomal abnormalities detected by FISH at study entry predicted overall survival. Eighteen patients experienced clonal evolution during follow-up. The rate of clonal evolution increased with duration of follow-up with only one occurrence in the first 2 years (n = 71; 1.4%) but 17 occurrences (n = 63; 27%) among patients tested after 5+ years. Clonal evolution occurred among 10% of ZAP-70-negative and 42% of ZAP-70-positive patients at 5+ years (P = .008).
Conclusion: This clinical trial confirms prospectively that cytogenetic abnormalities detected by FISH can predict overall survival for CLL patients at the time of diagnosis, but also suggests that many patients acquire new abnormalities during the course of their disease. Patients with higher ZAP-70 expression may be more likely to experience such clonal evolution. These findings have important implications for both clinical management and trials of early treatment for patients with high-risk, early-stage CLL.
Similar articles
- High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature.
Janssens A, Van Roy N, Poppe B, Noens L, Philippé J, Speleman F, Offner F. Janssens A, et al. Eur J Haematol. 2012 Jul;89(1):72-80. doi: 10.1111/j.1600-0609.2012.01790.x. Epub 2012 May 7. Eur J Haematol. 2012. PMID: 22509718 - Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis.
Brejcha M, Stoklasová M, Brychtová Y, Panovská A, Štěpanovská K, Vaňková G, Plevová K, Oltová A, Horká K, Pospíšilová Š, Mayer J, Doubek M. Brejcha M, et al. Leuk Res. 2014 Feb;38(2):170-5. doi: 10.1016/j.leukres.2013.10.019. Epub 2013 Oct 29. Leuk Res. 2014. PMID: 24246692 - Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia.
Zhang L, Znoyko I, Costa LJ, Conlin LK, Daber RD, Self SE, Wolff DJ. Zhang L, et al. Cancer Genet. 2011 Dec;204(12):654-65. doi: 10.1016/j.cancergen.2011.10.012. Cancer Genet. 2011. PMID: 22285017 - The use of fluorescence in situ hybridization (FISH) in chronic lymphocytic leukemia (CLL).
Gozzetti A, Crupi R, Tozzuoli D. Gozzetti A, et al. Hematology. 2004 Feb;9(1):11-5. doi: 10.1080/10245330310001652446. Hematology. 2004. PMID: 14965864 Review. - Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia.
Méhes G. Méhes G. Pathol Oncol Res. 2005;11(4):205-10. doi: 10.1007/BF02893852. Epub 2005 Dec 31. Pathol Oncol Res. 2005. PMID: 16388316 Review.
Cited by
- The spectrum of chromosomal translocations in the Arab world: ethnic-specific chromosomal translocations and their relevance to diseases.
Zedan HT, Ali FH, Zayed H. Zedan HT, et al. Chromosoma. 2022 Sep;131(3):127-146. doi: 10.1007/s00412-022-00775-2. Epub 2022 Jul 30. Chromosoma. 2022. PMID: 35907041 Free PMC article. Review. - Lymphocytosis and chronic lymphocytic leukaemia: investigation and management.
Devi A, Thielemans L, Ladikou EE, Nandra TK, Chevassut T. Devi A, et al. Clin Med (Lond). 2022 May;22(3):225-229. doi: 10.7861/clinmed.2022-0150. Clin Med (Lond). 2022. PMID: 35584829 Free PMC article. - Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy.
Zapatka M, Tausch E, Öztürk S, Yosifov DY, Seiffert M, Zenz T, Schneider C, Blöhdorn J, Döhner H, Mertens D, Lichter P, Stilgenbauer S. Zapatka M, et al. Haematologica. 2022 Mar 1;107(3):604-614. doi: 10.3324/haematol.2020.265777. Haematologica. 2022. PMID: 33691380 Free PMC article. - Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
Durak Aras B, Isik S, Uskudar Teke H, Aslan A, Yavasoglu F, Gulbas Z, Demirkan F, Ozen H, Cilingir O, Inci NS, Gunden G, Bulduk T, Erzurumluoglu Gokalp E, Kocagil S, Artan S, Akay OM. Durak Aras B, et al. Mol Cytogenet. 2021 Jan 6;14(1):2. doi: 10.1186/s13039-020-00522-1. Mol Cytogenet. 2021. PMID: 33407772 Free PMC article. - Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Woyach JA. Woyach JA. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):476-481. doi: 10.1182/hematology.2019001321. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808904 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials